Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04893837 · ClinicalTrials.gov registry record

Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)

A clinical trial of Brain Injuries, Traumatic, sponsored by University of Alabama at Birmingham.

Completed
Registry status
399
Enrollment target
2
Study locations

NCT04893837 is a study of Brain Injuries, Traumatic that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 399 participants, above the 237-participant average among 21 other Brain Injuries, Traumatic trials with a reported enrollment target (68% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04893837, a study of Brain Injuries, Traumatic, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
399 participants
Enrollment target
2
Study locations

Study Summary

MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.

Conditions Studied

Interventions

  • DEVICE Standard care plus infrascans

Study Locations (2)

Alabama

  • UAB Hospital - Birmingham

Arizona

  • University of Arizona - Tucson

Trial Details

FieldValue
Enrollment Target 399 participants
Start Date 2022-04-18
Est. Completion 2025-08-25

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT04893837

The ClinicalTrials.gov registry entry for NCT04893837 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 399 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 237-participant average among 21 other Brain Injuries, Traumatic trials with a reported enrollment target (68% higher). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Injuries, Traumatic appearing as the primary indexed condition, and to 1 intervention - of which Standard care plus infrascans is the first listed.

NCT04893837 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT04893837 about?

NCT04893837 is a clinical study titled "Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)". MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.

What is the current status of trial NCT04893837?

This trial is currently completed. The enrollment target is 399 participants. The study started on 2022-04-18. Estimated completion is 2025-08-25.

What conditions does trial NCT04893837 study?

This clinical trial studies the following conditions: Brain Injuries, Traumatic.

What interventions are being tested in trial NCT04893837?

The interventions under investigation include: Standard care plus infrascans (DEVICE).

Who is sponsoring clinical trial NCT04893837?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04893837 being conducted?

This trial has 2 study locations across Alabama, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Injuries, Traumatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.